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2012.12.0Abstract Background: Epidermal growth factor receptor (EGFR) and its downstream factors
KRAS and BRAF are mutated in several types of cancer, affecting the clinical response to EGFR
inhibitors. Mutations in the EGFR kinase domain predict sensitivity to the tyrosine kinase inhibitors
geﬁtinib and erlotinib in lung adenocarcinoma, while activating pointmutations inKRAS andBRAF
confer resistance to the anti-EGFR monoclonal antibody cetuximab in colorectal cancer. The devel-
opment of new generation methods for systematic mutation screening of these genes will allow more
appropriate therapeutic choices.
Purpose: Detection of KRAS mutation in Egyptian colorectal cancer (CRC) patients by the KRAS
StripAssay.1227786830.
(N.M. Kassem).
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38 Y. Abd El Kader et al.Methods: Examination of 20 colorectal cancer (CRC) patients is done to detect KRASmutations by
KRAS StripAssay. For the StripAssay, a mutant-enriched PCR was followed by hybridization to
KRAS-speciﬁc probes bound to a nitrocellulose strip.
Results: Among 20 patients, KRASmutations were identiﬁed in 80%of patients by theKRAS Strip-
Assay.
Conclusions: Our preliminary results suggest that KRAS StripAssay is an alternative to protocols
currently in use for KRAS mutation detection.
ª 2013 National Cancer Institute, Cairo University. Production and hosting by Elsevier B.V.
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The epidermal growth factor receptor (EGFR) plays a key role
as a receptor tyrosine kinase (TK), controlling several signal-
ing pathways that stimulate cell growth, proliferation and sur-
vival. Mutations involving the EGFR axis can cause its
constant activation, leading to uncontrolled cell proliferation.
Not surprisingly, EGFR mutations have been identiﬁed in sev-
eral types of cancer and it is a target of many anticancer ther-
apies, including small-molecule TK inhibitors (e.g., geﬁtinib
and erlotinib for lung cancer) and monoclonal antibodies
(e.g., cetuximab and panitumumab for colon cancer) [1]. Sev-
eral reports indicate that an increased gene copy number of
EGFR or mutations of genes responsible for downstream sig-
naling, especially KRAS, are important determinants of re-
sponse or resistance to anti-EGR antibodies [2].
The KRAS gene is located on the short (p) arm of chromo-
some 12 at position 12.1. KRAS is part of a group of three
homologous oncogenes and encodes a small 21 kDa protein
(p21Ras) involved in the transduction of external stimuli to
effector molecules across plasma membranes, downstream
from the EGFR. This protein has intrinsic guanosine triphos-
phatase (GTPase) activity, allowing inactivation after signal
transduction in the normal cellular environment [3]. Mutations
in the KRAS gene occur early in the development of many
cancers and are found in more than 90% of pancreatic adeno-
carcinomas, 40% of colorectal cancers (CRC) and 33% of
non-small cell lung carcinomas (NSCLC) [4].
Somatic point mutations of KRAS occurring early in CRC
tumorigenesis are thought to abolish GTPase activity, leading
to a constitutive activation of KRAS and inevitably to in-
creased and unregulated cellular proliferation and malignant
transformation [4,5]. Oncogenic mutations of the KRAS gene
are observed in 40% of sporadic CRC, and up to 90% of
these mutations are detected in codons 12 and 13 and less fre-
quently also in codons 61 and 63 [2].
Several retrospective analyses of tumor samples in CRC pa-
tients receiving anti-EGFR antibody treatment have shown
that patients with mutated KRAS did not beneﬁt from anti-
EGFR therapy [6,7]. Based on systematic reviews of the rele-
vant literature, the American Society of Clinical Oncology sug-
gested, in a Provisional Clinical Opinion in 2009, that when
KRAS mutations in codon 12 or 13 were detected in patients
with mCRC, such patients should not receive anti-EGFR anti-
body therapy as part of their treatment [8]. The European
Medicines Agency has also recognized these ﬁndings, and in-
deed also restricts the use of anti-EGFR antibody therapy only
to CRC patients with wild-type (wt) KRAS tumors [9].Accurate mutation detection depends on several factors,
including available tissue, DNA quality, DNA input, and tu-
mor cell percentage. When choosing an assay for routine
diagnostics, additional factors such as workload, time to re-
sults, hands-on time, dedicated equipment, costs, assay ﬂex-
ibility, and robustness of a technique need to be addressed
as well [13]. In most of the pathology laboratories, direct
sequencing, i.e., PCR followed by dideoxy sequencing, is
considered the gold standard for KRAS mutation detection.
However, this technique is not only laborious and time con-
suming, but sensitivity plays an important role. To reliably
test a sample, at least 20–30% of tumor cells are needed.
To date, there are several alternative assays available for
(KRAS) mutation detection, including ‘‘homebrew’’ assays,
such as high-resolution melting curve analysis (HRM) [14],
pyrosequencing [15], single nucleotide primer extension assay
[16], and allele-speciﬁc real-time PCR [17], and commercially
available assays, such as reverse hybridization test KRAS
StripAssay (Vienna Labs, Vienna, Austria) [18] and real-time
PCR-based Thera-Screen (Roche Diagnostics, Almere, the
Netherlands); all these assays greatly differ in sensitivity,
speciﬁcity, DNA input, time to results, hands-on time, ﬂex-
ibility, workload, and costs.
Therefore, in this study, we aimed to use the reverse hybrid-
ization StripAssay as an easy method for KRAS mutation
detection in fresh CRC samples in a small Egyptian
population.
Patients and methods
Study population
The current study was carried out on 20 newly diagnosed
Egyptian patients with colorectal carcinoma (CRC). Patients
were chosen during the period between October 2011 and
May 2012 among cases referred to the National Cancer Insti-
tute (NCI), Cairo University, after taking their informed con-
sents. The research was approved by the IRB of the NCI. They
were 6 (30%) males and 14 (70%) females. Their ages ranged
between 47 years and 72 years with a median of 56.5 years.
Exclusion criteria included pediatric age group, non-Egyptians
and patients with double malignancy. Diagnosis of colorectal
carcinoma (CRC) was based on excision biopsy from the af-
fected sites. Histopathological studies were done to conﬁrm
the diagnosis (Table 1). According to the Dukes classiﬁcation,
18 patients have stage A, one has stage B and one has stage C.
Only one patient has metastatic deposits in pericolic and para-
aortic LNs.
Table 1 Clinicopathologic features of the 20 cases with colorectal adenocarcinoma.
Sample id Gender Age (years) Site Grade Dukes stage Lymph nodes
A F 72 Colonic Low A Not aﬀected
B F 56 Rectosigmoid Low A Not aﬀected
C F 58 Sigmoid colon and mass
50 cm from anal verge
Low B Not aﬀected
D F 59 Colorectal Low A Not aﬀected
E F 60 Colonic High C Pericolic LNs and para-aortic
LNs showed metastatic deposits
F M 62 Colonic Low A Not aﬀected
G M 49 Colonic Low A Not aﬀected
H F 47 Colonic Low A Not aﬀected
I F 62 Colonic Low A Not aﬀected
J M 57 Colonic Low A Not aﬀected
K F 47 Colonic Low A Not aﬀected
L F 70 Rectal Low A Not aﬀected
M F 56 Colonic Low A Not aﬀected
N F 59 Colonic Low A Not aﬀected
O F 50 Colonic Low A Not aﬀected
P M 52 Colonic Low A Not aﬀected
Q M 49 Colonic Low A Not aﬀected
R F 47 Colonic Low A Not aﬀected
S F 62 Colorectal Low A Not aﬀected
T M 53 Colonic Low A Not aﬀected
F = female and M=male.
Table 2 Molecular genetic alterations.
Sample ID
(No. of patients = 20)
KRAS mutation genotype
A Codon 12 Ala + 12 Val
B Codon 12 Asp + 12 Ser
C Codon 12 Asp + 12 Cys + 12 Ser + 12 Va
D Codon 12 Ser + 12 Val + 13 Asp
E Codon 12 Asp + 12 Ser
F Codon 12 Val
G No mutation
H Codon 12 Ala + 12 Asp
I Codon 12 Val
J No mutation
K Codon 12 Val
L Codon 12 Asp + 12 Ser
M Codon 12 Val
N Codon 12 Ala + 12 Asp
O Codon 12 Asp + 12 Cys + 12 Ser + 12 Va
P No mutation
Q Codon 12 Ser + 12 Val + 13 Asp
R Codon 12 Ala + 12 Val
S No mutation
T Codon 12 Asp + 12 Ser
Ala, alanine; Asp, aspartic acid; Cys, cysteine; Ser, serine; Val,
valine.
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Fresh surgical specimens were obtained. DNA was extracted
from tissue by (QIAamp DNA Mini Kit) Cat. No. 51304
according to the manufacturer’s instructions. DNA concentra-
tion and purity was deﬁned using the Nanodrop 1000 (Isogen,
Sint-Pieters-Leeuw, Belgium) with a range of 55–110 ng/ll. All
genomic DNAs were stored at 80 C until further research.
KRAS StripAssay
The KRAS StripAssay kit (Lot. 5-590) was kindly provided
by the Vienna Lab of Austria. All procedures were con-
ducted according to the manufacturer’s instructions in sterile
area (laminar ﬂow) to avoid false positive results due to con-
tamination. Brieﬂy, for each PCR reaction a total volume of
25 lL was used. PCR products were ampliﬁed in a tube con-
taining 15 lL of ampliﬁcation mix, 5 lL of diluted Taq
DNA polymerase and 5 lL of DNA template. The cycling
conditions were 94 C for 2 min, 35 cycles of 94 C for
60 s, 70 C for 50 s, 56 C for 50 s and 60 C for 60 s, with
ﬁnal extension at 60 C for 3 min. Following hybridization
(45 C, shaking water bath), stringent washing (45 C, shak-
ing water bath) and color development (room temperature),
the results were interpreted using the enclosed Collector
sheet.
Statistical analysis
Quantitative data were presented as minimum, maximum,
mean, median and standard deviation (SD) values. Qualitative
data were presented as frequencies and percentages. The
Chi-square (·2) test was used for studying the comparisons be-
tween different qualitative variables.l
lResults
The study included 6 males and 14 females with a median age
of 56.5 years (range from 47 years to 72 years). The primary
locations of tumors were the colon (n= 16) and the rectum
(n= 4). Sixteen patients had KRAS mutations representing
(16/20) 80% of the study sample. Females showed a statisti-
cally signiﬁcantly higher prevalence of mutation than males
Figure 1 KRAS mutations present on StripAssay. (A) Positive lines at positions 1 and 8. (B) Positive lines at positions 3 and 7. (C)
Positive lines at positions 3, 4, 7 and 8. (D) Positive lines at positions 7, 8 and 9. (E) Positive lines at positions 3 and 7. (F) Positive lines at
position 8. (G) No mutation. (H) Positive lines at positions 1 and 3. (I) Positive lines at position 8. (J) No mutation.
40 Y. Abd El Kader et al.as the KRAS mutations were detected in 2/6 (33.3%) of males
and 14/14 (100%) of females. Fourteen patients 14/20 (70%)
had a single mutation site at codon 12, two patients 2/20
(10%) in codons 12 and 13 and 4 patients 4/20 (20%) showed
no mutations (Table 2 and Fig. 1).
Discussion
The recent advice from the American Society of Clinical
Oncology (ASCO) and a European expert panel to perform
KRAS mutation detection before therapy with cetuximab in
metastatic colorectal cancer [8] and in stage II and III colon
cancer [10] respectively, has made the need urgent for a sensi-
tive, ﬂexible, and fast assay that is easy to implement in daily
practice. Therefore, the commercially available StripAssay was
used in this study to detect KRAS mutations.
Sixteen of the 20 examined patients with CRC harbored a
mutated KRAS gene. The most striking observation is that al-
most all mutations occurred in codon 12 of the KRAS gene as
it was found in 14 cases and only two patients had the muta-
tion in both codons 12 and 13. In 4 cases KRAS gene muta-
tions could not be detected in the tumor DNA, although
histologically these tumors did not differ from the tumors with
a mutated KRAS gene.
The StripAssay is based on mutant-enriched PCR followed
by reverse hybridization. The mutant-enriched PCR is based
on the clamping of the wild-type sequence by PNA nucleo-
tides; therefore, only the mutant DNA template is ampliﬁed.
Such a sensitive technique could detect small subpopulations
of tumor cells carrying mutant alleles within a majority of
wild-type tumor cells. Although KRAS mutation is generally
accepted as an early event in colon carcinogenesis [11], tumor
heterogeneity is a known feature [12]. Baldus et al. [12] have
recently reported that mutations are differentially present in
different areas of the tumor as well as in positive lymph nodes
and metastases. The clinical relevance of this ﬁnding is not
fully understood, but it could greatly contribute to difﬁculty
in therapy decision making. Mutated clones could be preferen-
tially detected with the StripAssay, while the remaining unde-
tectable with standard techniques such as direct sequencing
and SNaPshot, even when sufﬁcient tumor cells are present.For colon cancer diagnostics, in which sensitivity is gener-
ally not an issue, and when capillary electrophoresis facilities
are already available, SNaPshot can be as valuable as direct
sequencing. Workﬂow, time to results, hands-on time, and
costs do not vary much between both techniques. However,
the multiplex possibilities of the SNaPshot can reduce DNA
input, costs, and workload. Thus, SNaPshot is a good alterna-
tive for direct sequencing for KRAS mutation detection in co-
lon cancer patients in daily diagnostic practice. However, when
sensitivity is an important issue, such as in the case of lung
cytology samples, or for small laboratories without dedicated
equipment, highly sensitive techniques such as the StripAssay
should be considered due to its high sensitivity, rapidity, and
ease to perform. Nevertheless, one should be aware of the
false-positivity risks of such a technique and perform assays
in duplicate to avoid false positives [13]. Thus, the high sensi-
tivity of the StripAssay could be its biggest caveat, and one
should be very cautious when carrying out such a sensitive as-
say. It might well be that even more expertise, more restricted
laboratory discipline, and special additional precautions are
necessary to circumvent false positivity due to sample contam-
ination [13].
The workﬂow of the StripAssay is easy and time to results
after DNA isolation is half a working day. This assay also does
not require any dedicated equipment. Thus, results can be eas-
ily obtained.
This research warrants further, larger scale studies.Acknowledgements
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